Overview
The main objective of this study is to compare two post-stroke/TIA (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected. The first strategy is the current/usual strategy in each participating centre and the second strategy consists in starting the post-stroke/TIA imaging assessment by a whole-body, low-dose angiography and subsequently resorting to elements of the usual strategy if required.
Description
The secondary objectives are:
- To compare the patient pathways between the two arms in terms of time to diagnosis, and duration of hospitalization.
- To compare the consumption of imaging exams (number and type) and total body irradiation between the two arms.
- To compare the diagnostic efficiency between the two arms in terms of detection of predefined lesions, and performance ratios.
- To study the thickness of the left atrial wall as a risk factor for permanent atrial fibrillation.
- To compare the distribution of suspected neoplasms between the two groups, as well as the number of detected incidentalomas.
- To compare the survival and the incidence of new cardiovascular events between the two arms at 12 months and 36 months.
- To compare the quality of life between the two arms at 12 months and 36 months.
Eligibility
Inclusion Criteria:
- The patient was informed about the implementation of the study, its objectives, constraints and patient rights
- The patient has given free and informed consent and signed the consent
- Patient affiliated with or beneficiary of a health insurance plan
- Patient available for 36 months of follow-up
- The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage
Exclusion Criteria:
- The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study.
- Patient under guardianship or judicial protection
- Refusal to sign the consent
- Inability to correctly inform the patient or his/her trusted person about the study
- The patient is pregnant, parturient, or breastfeeding
- The patient has a contraindication for a treatment used in this study
- Known allergy to contrast medium or severe allergy to iodine
- Known active malignancy or history of cancer treatment
- The patient has already undergone a full body scanner in the previous three months
- Renal failure with creatinine clearance below 60 ml / min
- Monoclonal immunoglobulin
- History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia)
- Emergency situations that hamper the planned course of the study